Pengembangan Metode PCR Multipleks untuk Analisis Genotipe Null Gen GSTM1/GSTT1 pada Pasien Tuberkulosis

  • Kinasih Prayuni Universitas YARSI
  • Intan Razari Universitas YARSI
  • Silviatun Nihayah Universitas YARSI
  • Syafrizal Rumah Sakit Umum Pasar Rebo
  • Rika Yuliwulandari Universitas YARSI
Keywords: Genotipe null, GSTM1, GSTT1, Hepatotoksisitas, Tuberkulosis


Tuberculosis (TB) remains Indonesia's leading infectious disease. Hepatotoxicity is the most common side effect of TB first-line medication therapy in TB patients. GSTM1 and GSTT1 are glutathione S-transferase (GST) genes involved in the detoxification of various toxic compounds such as drugs. The development of fast and simple methods for null genotyping of GSTM1/GSTT1 could facilitate large pharmacogenetic studies and the clinical application of personalized drug dose adjustment according to the patient's genetic profile. The aim of this research was to develop a multiple PCR method for simultaneous amplification of GSTM1/GSTT1 genes for molecular analysis. A total of 25 samples of TB patients were used to validate the method consisting of TB patients with hepatotoxicity and without hepatotoxicity. Our result showed the genotype frequency of the GSTM1 null genotype was 90% in TB patients with hepatotoxicity and 100% in TB patients without hepatotoxicity. The frequency of the GSTT1 null genotype in TB patients with hepatotoxicity was 90%, whereas in TB patients without hepatotoxicity was 80%. The sequencing results on the positive samples showed a similarity of 99% to the GenBank NCBI. Our study was successful in detecting GSTM1 and GSTT1 null genotypes using the multiplex PCR method in TB patients. Further study needs to be done with larger sample of TB patients.


Download data is not yet available.


World Health Organization(WHO). Global Tuberculosis Report 2021. Geneva, Switzerland; 2021.

Chatterjee S, Lyle N, Mandal a, Kundu S. GSTT1 and GSTM1 gene deletions are not associated with hepatotoxicity caused by antitubercular drugs. J Clin Pharm Ther [Internet]. 2010;35(4):465–70. Available from:

Tostmann A, Boeree MJ, Aarnoutse RE, De Lange WCM, Van Der Ven AJ a M, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: Concise up-to-date review. Journal of Gastroenterology and Hepatology (Australia). 2008;23(2):192–202.

Da Fonseca RR, Johnson WE, O’Brien SJ, Vasconcelos V, Antunes A. Molecular evolution and the role of oxidative stress in the expansion and functional diversification of cytosolic glutathione transferases. BMC Evol Biol. 2010;10(1).

Saitou M, Ishida T. Distributions of the GSTM1 and GSTT1 null genotypes worldwide are characterized by latitudinal clines. Asian Pacific Journal of Cancer Prevention. 2015;16(1):355–61.

Huang YS. Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis drug-induced liver injury. Expert Opin Drug Metab Toxicol. 2007;3(1):1–8.

Li C, Long J, Hu X, Zhou Y. GSTM1 and GSTT1 genetic polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity: An updated meta-analysis. European Journal of Clinical Microbiology and Infectious Diseases. 2013;32(7):859–68.

Ambreen K, Sharma R, Singh KP, Abbas1 M, Kumar S. Association of GSTM1, GSTT1 and CYP2E1 Gene Polymorphisms with Antituberculosis Drug Induced Hepatotoxicity in North Indian Population. Int J Health Sci Res. 2014;4:149–60.

Kasthurinaidu SP, Ramasamy T, Ayyavoo J, Dave DK, Adroja DA. GST M1-T1 null allele frequency patterns in geographically assorted human populations:A phylogenetic approach. PLoS One. 2015;10(4): e0118660.

World Health Organization. Treatment of tuberculosis. Geneva, Switzerland; 2010. 160 p.

Benichou C. Criteria of drug-induced liver disorders Report of an International Consensus Meeting. J Hepatol. 1990;11:272–6.

Shen Z, Qu W, Wang W, Lu Y, Wu Y, Li Z, et al. MPprimer: a program for reliable multiplex PCR primer design. BMC Bioinformatics. 2010;11(1):143.

Hawkins SFC, Guest PC. Multiplex analyses using real-time quantitative PCR. In: Methods in Molecular Biology. Humana Press Inc.; 2017. p. 125–33.

Kim MS, Kang HJ, Park HJ, Yook YJ, Han BD, Kim CW, et al. Development of multiplex PCR method for the analysis of glutathione S-transferase polymorphism. Mol Diagn Ther. 2011;15(5):285–92.

Rychlik W, Spencer W, Rhoads R. Optimization of the annealing temperature for DNA amplification in vitro. Vol. 18, Nucleic Acids Research. 1990.

Park M, Won J, Choi BY, Lee CJ. Optimization of primer sets and detection protocols for SARS-CoV-2 of coronavirus disease 2019 (COVID-19) using PCR and real-time PCR. Exp Mol Med. 2020 Jun 1;52(6):963–77.

Prayuni K, Razari I, Yuliwulandari R. Glutathione S-transferase M1 and T1 null allele frequencies among Indonesian ethnics toward improved disease risk assessment. Environ Toxicol Pharmacol. 2019;65:14-17.

Roy B, Chowdhury a, Kundu S, Santra a, Dey B, Chakraborty M, et al. Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 “null” mutation. J Gastroenterol Hepatol. 2001;16(9):1033–7.

Leiro V, Fernanndez-Villar A, Valverde D, Constenla L, Vazzquez R, Pineiro L, et al. Influence of glutathione S-transferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug-induced hepatotoxicity in a Caucasian population. Liver International. 2008;28(6):835–9.

Singla N, Gupta D, Birbian N, Singh J. Association of NAT2, GST and CYP2E1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity. Tuberculosis. 2014;94(3):293–8.

Huang YS, Su WJ, Huang YH, Chen CY, Chang FY, Lin HC, et al. Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J Hepatol. 2007;47(1):128–34.

Chanhom N, Udomsinprasert W, Chaikledkaew USA, Mahasirimongkol S, Wattanapokayakit S, Jittikoon J. GSTM1 and GSTT1 genetic polymorphisms and their association with antituberculosis drug-induced liver injury. Biomed Rep. 2020;12(4):153–62.

Jaramillo-Rangel G, Ortega-Martínez M, Cerda-Flores RM, Barrera-Saldaña H a. Polymorphisms in GSTM1, GSTT1, GSTP1, and GSTM3 genes and breast cancer risk in northeastern Mexico. Genetics and Molecular Research. 2015;14(2):6465–71.

Tang SW, Lv XZ, Zhang Y, Wu SS, Yang ZR, Xia YY, et al. CYP2E1, GSTM1 and GSTT1 genetic polymorphisms and susceptibility to antituberculosis drug-induced hepatotoxicity: A nested case-control study. J Clin Pharm Ther. 2012;37(5):588–93.

Crossley BM, Bai J, Glaser A, Maes R, Porter E, Killian ML, et al. Guidelines for Sanger sequencing and molecular assay monitoring. Journal of Veterinary Diagnostic Investigation. 2020 Nov 1;32(6):767–75.

How to Cite
Prayuni, K., Razari, I., Nihayah, S., Syafrizal, & Yuliwulandari, R. (2023). Pengembangan Metode PCR Multipleks untuk Analisis Genotipe Null Gen GSTM1/GSTT1 pada Pasien Tuberkulosis. ARTERI : Jurnal Ilmu Kesehatan, 4(4), 200-206.